Prostate Cancer
Conditions
Keywords
castrate resistant
Brief summary
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response and Serum PSA progression)
Interventions
DRUGGTx-758
two GTx 758 tablets per day
Sponsors
GTx
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Be over 18 years of age 2. Be able to communicate effectively with the study personnel 3. Have histologically confirmed prostate cancer 4. ECOG performance status of 0 to 2 5. Have been treated with ADT(chemical or surgical) for at least 6 months 6. Have castrate level of serum total testosterone (\<50 ng/dL) 7. Have a history of serum PSA response after initiation of ADT, serum PSA response is at least a 90% reduction in serum PSA to \<10 ng/mL OR undetectable level of serum PSA (less tan or =0.2 ng/mL) 8. Have rising serum PSA on two successive assessments at least 2 weeks apart and serum PSA levels ≥ 2 ng/mL or 2ng/mL and a 25% increase over the nadir after the initiation of ADT 9. Be continued on androgen deprivation therapy throughout this study 10. Give written informed consent prior to any study specific procedures 11. Subjects must agree to use acceptable methods of contraception: oIf their female partners are pregnant or lactating acceptable methods of contraception from the time of the first administration of study medication until 3 months following administration of the last dose of study medication must be used. Acceptable methods are: Condom used with spermicidal foam/gel/film/cream/suppository. If the subject has undergone surgical sterilization (vasectomy with documentation of azospermia) a condom with spermicidal foam/gel/film/cream/suppository should be used. oIf the male subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 3 months following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository \[i.e. barrier method of contraception\], surgical sterilization (vasectomy with documentation of azospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}. oIf the female partner has undergone documented tubal ligation (female sterilization), a barrier method {condom used with spermicidal foam/gel/film/cream/suppository} should also be used. oIf the female partner has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS) and a barrier method {condom with spermicidal foam/gel/film/cream/suppository} should also be used.
Exclusion criteria
1. Known hypersensitivity or allergy to estrogen or estrogen like drugs; 2. Have symptomatic metastatic prostate cancer 3. Any disease or condition (medical or surgical) which might compromise the hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk; 4. History of abnormal blood clotting, Factor V Leiden clotting disorder, thrombotic disease (venous or arterial thrombotic events such as history of stroke, deep vein thrombosis (DVT), and/or pulmonary embolus (PE)) 5. Symptomatic congestive heart failure (NYHA Class III - IV), unstable angina pectoris, cardiac arrhythmia 6. The presence of consistently abnormal laboratory values which are considered clinically significant. In addition, no subject with liver enzymes (ALT or AST) above 2 times the ULN, total bilirubin above 2 times the ULN, or serum creatinine above 1.5 ULN will be admitted to the study 7. Received an investigational drug within a period of 90 days prior to enrollment in the study 8. Received the study medication previously 9. Currently taking testosterone, testosterone-like agents, or antiandrogens,including 5-alpha reductase inhibitors (may be eligible if allow a 6 week washout period after stopping antiandrogens); 10. History of prior treatment of cancer chemotherapy agent (other than hormone therapy) or radiopharmaceutical for prostate cancer. 11. Have taken ketoconazole within the previous 12 months prior to randomization into this study 12. Have taken diethylstilbestrol or other estrogen products, ketoconazole, or abiraterone within the previous 12 months prior to randomization into this study 13. Have taken body building or fertility supplements within 4 weeks of admission into the study 14. Have been previously diagnosed with cancer (other than prostate cancer, superficial bladder cancer, or non-melanoma skin cancer).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decline in Serum PSA | 30 days |
Countries
United States
Participant flow
Recruitment details
18 subjects were enrolled with 7 subjects screen failing and 2 subjects randomized but not treated, for a total of 11 subjects treated. Outputs generated from previous company only provided data for the 11 subjects randomized. Program was halted.
Participants by arm
| Arm | Count |
|---|---|
| 1000 mg GTx-758 BID subjects will receive daily doses of 1000 mg GTx-758
GTx-758: two GTx 758 tablets per day | 9 |
| Total | 9 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 2 |
| Overall Study | Randomized not Treated | 2 |
| Overall Study | Screen failure | 7 |
| Overall Study | Study terminated by Sponsor | 7 |
Baseline characteristics
| Characteristic | 1000 mg GTx-758 BID |
|---|---|
| Age, Continuous | 73.3 years STANDARD_DEVIATION 10.6 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 8 Participants |
| Sex/Gender, Customized Male | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 9 |
| other Total, other adverse events | 7 / 9 |
| serious Total, serious adverse events | 1 / 9 |
Outcome results
Primary
Decline in Serum PSA
Time frame: 30 days
Population: Treated Patients
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 1000 mg GTx-758 BID | Decline in Serum PSA | 2 consecutive 50% or more decline | 3 Participants |
| 1000 mg GTx-758 BID | Decline in Serum PSA | 1 50% or more decline without confirmation in next visit | 1 Participants |
| 1000 mg GTx-758 BID | Decline in Serum PSA | No 50% or more decline observed | 5 Participants |